The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/23752

Please be advised that this information was generated on 2019-12-22 and may be subject to change.
A Mutation in COL9A2 Causes Multiple Epiphyseal Dysplasia (EDM2)

YASUTERU MURAGAKI,* EDWIN C. M. MARIMAN,* SYLVIA E. C. VAN BEERSUM, * MERJA PERALÄ, c JAN B. A. VAN MOURIK, d MATTHEW L. WARMAN, e BEN C. J. HAMEL, b AND BJORN R. OLSEN a

a Department of Cell Biology
Harvard Medical School
Boston, Massachusetts 02115

b Department of Human Genetics
University Hospital Nijmegen
6500 HB Nijmegen
The Netherlands

c Department of Medical Biochemistry
University of Turku
20520 Turku
Finland

d Department of Orthopaedic Surgery
St. Joseph Hospital
5500 MB Veldhoven
The Netherlands

e Department of Genetics
Case Western Reserve University School of Medicine
Cleveland, Ohio 441067

Multiple epiphyseal dysplasia (MED) is an autosomal dominant skeletal disorder characterized by early onset osteoarthritis with short stature and stubby fingers. Linkage analyses have identified at least three genetic loci for MED: EDM1 on chromosome 19,1 EDM2 on chromosome 1,2 and an additional locus.3 EDM1 is caused by mutations in the cartilage oligomeric matrix protein gene (COMP);4 mutations in COMP have also been demonstrated in pseudoachondroplasia (PSACH).5 We examined a large Dutch family with MED and found that the disorders in this family is caused by a mutation in the α2(IX) collagen gene.6 The characteristic clinical features of affected individuals include pain in the knee joints and waddling gait between 3 and 6 years of age. X rays of knee joints showed the typical changes of multiple epiphyseal dysplasia: flattened, irregular epiphyses, varus/valgus deformity of the knees, and gradually appearing osteoarthritis with or without loose bodies. Linkage analysis with microsatellite markers from the EDM1 (D19S199, D19S212, D19S215, D19S222) and EDM2 (D1S186 and MYCL) regions showed significant linkage between the disease and EDM2.
To find the causative mutation we performed RT-PCR with total RNA from short-term cultured chondrocytes, obtained during arthroscopic surgery, and from EBV transformed lymphoblasts from an affected patient. First-strand cDNAs were synthesized with oligo(dT) primers using the Superscript Preamplification System (GIBCO BRL). Since the EDM2 locus includes COL9A2, PCR primers were designed to amplify the approximately 2-kb cDNA coding for α2(IX) collagen in four overlapping fragments. Second-round PCR had to be used to amplify overlapping cDNA fragments encoding the NC2, COL2, NC3, and COL3 domains and the carboxyl half of the signal peptide of the α2(IX) collagen chain with nested primers. When the PCR products were analyzed on 2% agarose gels all products were the same size from affected and unaffected individuals except one containing coding sequences for the COL3 domain. This product migrated as a single band from unaffected individuals and as a double band from affected individuals. Dideoxy-nucleotide cycle sequenc-
Figure 2. Diagram showing the potential fates of collagen IX trimers containing a mutated α2(IX) chain. Within chondrocytes (grey oval) mutated α2(IX) chains are likely to be incorporated into trimers. Such trimers would have a folding defect in the COL3 domain and may be degraded intracellularly, or be secreted and incorporated into fibrils. The abnormal conformation of their COL3 domains may disrupt the normal function of such molecules on the fibrillar surface.
ence of the HphI site (data not shown). We conclude, therefore, that the MED in this family is caused by a splice donor site mutation in intron 3 of the α2(IX) collagen gene, leading to exon skipping during RNA splicing and an in-frame loss of 12 amino acid residues within a triple-helical domain of the polypeptide. The deletion may not have an effect on polypeptide synthesis or formation of collagen IX trimers; however, the mutation may have a dominant negative effect either at the level of protein secretion or supramolecular assembly (Fig. 2).

REFERENCES


